智通财经APP讯，火山邑动国际控股(01715)公布，公司股份于联交所买卖的英文股票简称将 由"VOLCANO SPRING"更改为"AI HEALTH TECH"及中文股票简称将由"火山邑动国际控股"更改为"智 慧健康科技"，自 2025年 8月 13日上午九时正起生效。公司于联交所的股份代号维持不变，为 「1715」。 （原标题：火山邑动国际控股(01715)股票简称将更改为"智慧健康科技"） ...

格隆汇8月8日丨火山邑动国际控股(01715.HK)公告，董事会欣然宣布，根据开曼群岛公司注册处处长发 出更改名称注册证书，建议将公司英文名称由"Volcano Spring International Holdings Limited"更改为"AI Health Technology Limited"，并将中文名称更改为"智慧健康科技有限公司"以取代其现有中文名称"火山 邑动国际控股有限公司"一事已于2025年7月4日起生效。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 AI Health Technology Limited 智慧健康科技有限公司 （於開曼群島註冊成立的有限公司） (前稱 Volcano Spring International Holdings Limited 火山邑動國際控股有限公司) 本 公 司 股 份 於 聯 交 所 買 賣 之 英 文 股 票 簡 稱 將 由「VOLCANO SPRING」更 改 為「AI HEALTH TECH」及 中 文 股 票 簡 稱 將 由「火 山 邑 動 國 際 控 股」更 改 為「智 慧 健 康 科 技」，自 二 零 二 五 年 八 月 十 三 日 上 午 九 時 正 起 生 效。本 公 司 於 聯 交 所 之 股 份 代 號 維 持 不 變，為「1715」。 （股份代號：1715） 更 改 公 司 名 稱、股 票 簡 稱 及公司網站 茲 提 述 智 慧 健 ...

Core Viewpoint - Volcano International Holdings (01715) announced a proposal for a capital restructuring involving a share capital reduction and a share split to address accumulated losses and improve financial position [1] Group 1: Capital Restructuring Details - The proposed capital restructuring includes a share capital reduction by cancelling HKD 0.249 of the paid-up capital for each issued share, reducing the nominal value from HKD 0.25 to HKD 0.001 [1] - Following the capital reduction, the company plans to split the remaining unissued shares with a nominal value of HKD 0.25 into 250 new shares, each with a nominal value of HKD 0.001 [1] - The proceeds from the capital reduction will be used to offset the accumulated losses as of the effective date of the capital reduction, thereby reducing the company's cumulative losses [1]

Volcano Spring International Holdings Limited 火山邑動國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1715） 建議股本重組 董 事 會 建 議 向 股 東 提 呈 建 議 進 行 股 本 重 組，當 中 涉 及： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 一般事項 本 公 司 將 召 開 及 舉 行 股 東 特 別 大 會 以 供 股 東 考 慮 及 酌 情 批 准 股 本 重 組。一 份 載 有（其 中 包 括）股 本 重 組 詳 情、連 同 召 開 股 東 特 別 大 會 之 通 告 及 相 關 代 表 委 任 表 格 之 通 函，預 期 將 於 二 零 二 五 年 八 月 十 五 日（星 期 五）或 之 前 寄 發 予 股 東。 – 1 – (i) 股 本 削 減，據 此 透 過 註 銷 每 股 已 發 行 股 份 之 ...

Group 1 - The core viewpoint of the news highlights the significant stock performance of Volcano International Holdings, with a notable increase in share price and strong year-to-date growth compared to the Hang Seng Index [1] - As of July 23, the Hang Seng Index rose by 1.62% to 25,538.07 points, while Volcano International Holdings' stock price increased by 12.5% to HKD 0.36 per share, with a trading volume of 3.66 million shares and a turnover of HKD 1.24 million [1] - Over the past month, Volcano International Holdings has seen a cumulative increase of 6.67%, and a year-to-date increase of 71.37%, outperforming the Hang Seng Index by 25.27% [1] Group 2 - Financial data shows that as of December 31, 2024, Volcano International Holdings achieved total revenue of HKD 91.885 million, representing a year-on-year growth of 8.91% [1] - The company reported a net profit attributable to shareholders of -HKD 35.85 million, with a year-on-year increase of 27.31%, and a gross margin of 7.06% [1] - The company's debt-to-asset ratio stands at 69.16%, indicating a relatively high level of leverage [1] Group 3 - Currently, there are no institutional investment ratings for Volcano International Holdings [2] - In terms of industry valuation, the average price-to-earnings (P/E) ratio for the household appliances and goods sector is 13.18 times, with a median of 1.62 times [2] - Volcano International Holdings has a P/E ratio of -2.98 times, ranking 70th in the industry, while other companies in the sector have P/E ratios ranging from 1.61 to 3.87 times [2] Group 4 - Volcano International Holdings is a modern large-scale enterprise platform focused on the health industry, primarily engaged in the research, production, sales, and service of health products [2] - The company is listed on the Hong Kong Stock Exchange under the stock code 1715.HK and implements a scientific health strategy, relying on modern technology to establish a comprehensive health product system [2] - Volcano International collaborates with research institutions to continuously conduct health research, aiming to create scientifically-backed health products [2]

Financial Performance - Revenue for the year ended December 31, 2024, increased by 8.9% to RMB 91.9 million from RMB 84.4 million in 2023[12] - Net loss for the year was RMB 36.0 million, an improvement from a net loss of RMB 49.3 million in 2023[13] - Total assets decreased to RMB 137.5 million in 2024 from RMB 165.7 million in 2023, representing a decline of 17%[10] - The company recorded a gross profit of RMB 6.5 million, down from RMB 21.2 million in 2023, indicating a significant decrease in gross margin[9] - Basic and diluted loss per share improved to RMB 0.37 in 2024 from RMB 0.73 in 2023[13] - Total liabilities decreased to RMB 95.1 million in 2024 from RMB 107.5 million in 2023, a reduction of approximately 11.5%[10] - The gross profit margin decreased to 7.1% from 25.1% for the year ended December 31, 2023, primarily due to changes in the product mix and inventory impairment losses[29] Revenue Sources - Revenue from health-related products accounted for 49.1% of total revenue, significantly up from 23.4% in the previous year[21] - Direct sales from consignment stores decreased by 20.9% to RMB 14.4 million, attributed to reduced consumer spending amid economic challenges[24] - Sales revenue from television platforms dropped by 76.2% to RMB 3.5 million, reflecting decreased consumer expenditure through this channel[26] - Revenue from online platforms fell by 64.9% to RMB 7.9 million, mainly due to poor economic conditions affecting consumer spending[27] - Revenue from physical sales locations surged by 148.7% to RMB 65.4 million, driven by the launch of health-related products[28] Cost Management - The company reported a decrease in sales costs to RMB 85.4 million in 2024 from RMB 63.2 million in 2023, reflecting a strategic focus on cost management[9] - Administrative expenses decreased by 22.9% to RMB 14.5 million, primarily due to cost control measures[34] - Research and development expenses decreased by 14.5% to RMB 5.9 million from RMB 6.9 million for the year ended December 31, 2023, primarily due to cost control measures[35] - Financial costs decreased by 45.5% to RMB 4.2 million from RMB 7.7 million for the year ended December 31, 2023, mainly due to the repayment of a loan in July 2024[37] Corporate Governance - The company is committed to establishing good corporate governance practices to enhance transparency and accountability[81] - The board focuses on internal controls and fair disclosure to ensure compliance with legal and business standards[81] - The company aims to create more value for shareholders through effective corporate governance[81] - The company appointed Mr. Zhao Jie as the Executive Director and Chairman on August 1, 2024, ensuring compliance with the corporate governance code regarding the separation of roles[83] - The board has established three committees to assist in fulfilling its responsibilities and promoting effective management[97] ESG and Sustainability - The environmental, social, and governance (ESG) report covers the group's performance from January 1, 2024, to December 31, 2024[153] - The report adheres to the guidelines set by the Hong Kong Stock Exchange for ESG reporting, ensuring the relevance and importance of key performance indicators[154] - Key environmental issues identified include greenhouse gas emissions, energy consumption, and waste management, which are prioritized for monitoring and resolution[163] - The company generated a total of 107 tons of greenhouse gas emissions during the reporting period, a decrease from 168.18 tons in 2023, resulting in an emissions density of 1.55 tons of CO2 per employee compared to 0.82 tons in 2023[174] - The company has set a target to reduce greenhouse gas emissions by 5% by 2027, based on the 2022 baseline[177] Employee and Labor Relations - The total number of full-time employees decreased to 69 as of December 31, 2024, down from 205 as of December 31, 2023[195] - Employee turnover rates for males increased to 35.3% in 2024 from 33.8% in 2023, while female turnover rates rose to 11.5% from 6.0%[196] - The company complies with Chinese labor laws and has not faced any significant disputes or operational disruptions due to labor issues during the reporting period[200] - The company provides social insurance for employees, including retirement, medical, and unemployment benefits, in accordance with applicable Chinese laws[200] Strategic Initiatives - The company plans to establish a joint venture with Shanghai Yougu Health Technology Co., Ltd. to expand into the health industry, focusing on biomedicine and AI technology[15] - The company is exploring potential opportunities to diversify its business segments and create value for shareholders[15] - The group completed a placement of 42,310,000 shares at a price of HKD 0.52 per share, raising approximately HKD 21.0 million, with HKD 20.0 million allocated for repaying other borrowings[63]

投向以早期及成长期为主的美业及产业上下游相关领域，兼具科技创新和可持续价值的品 牌。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息， 欧莱雅 日前 宣布与天图投资合作成立美丽领航基金，该基金将投向以早期及 成长期为主的美业及产业上下游相关领域，兼具科技创新和可持续价值的品牌，以支持中国蓬勃发展 的美业市场，为中国乃至全球消费者创造更多更美的体验。 作为 中国最早专注于消费领域的投资机构，天图投资在消费领域积累了丰富的行业资源，并形成了 系统化的投研体系。通过行业洞察积累和产业资源链接，此次合作将促进中国美业生态系统的增长和 创新。欧莱雅作为基金的基石投资者，其强大的研发创新能力与全球化视野将为利益相关方的可持续 发展提供助力。 欧莱雅北亚总裁及中国首席执行官博万尚表示： "中国正引领全球美妆市场的未来，因此，'投资中 国，就是投资未来'成为我们的核心战略。此次合作彰显了我们与中国美妆生态圈携手创新、合作共 赢的坚定承诺。我们相信，欧莱雅的全球美妆领导地位与天图投资的专业实力强强联合，必将激发创 新活力，催生突破性美妆理念，推动中国品牌走向世界舞 ...

Financial Performance - The total revenue for the six months ended June 30, 2024, increased by 8.2% to approximately RMB 55.9 million, compared to RMB 51.7 million for the same period in 2023[6]. - The gross profit margin decreased, leading to a net loss of RMB 23.1 million for the current period, compared to a net loss of RMB 20.6 million for the same period in 2023[4]. - Revenue from health products accounted for 59.7% of total revenue, increasing from 37.0% in the previous year, with sales amounting to RMB 33.4 million[6]. - Revenue for the six months ended June 30, 2024, was RMB 55,949,000, an increase of 8.6% compared to RMB 51,710,000 for the same period in 2023[31]. - Gross profit decreased to RMB 6,298,000, down 62.4% from RMB 16,725,000 year-on-year[31]. - Operating loss for the period was RMB 19,784,000, compared to an operating loss of RMB 15,014,000 in the previous year, reflecting a deterioration of 31.5%[31]. - Total comprehensive loss for the period was RMB 23,394,000, compared to RMB 20,733,000 in the same period last year, representing an increase of 12.8%[32]. - The company reported a loss before tax of RMB 23,122,000 for the six months ended June 30, 2024, compared to a loss of RMB 20,225,000 for the same period in 2023[46][48]. - The company had a net loss attributable to owners of RMB 23,149,000 for the six months ended June 30, 2024, compared to a loss of RMB 20,610,000 for the same period in 2023[50]. Revenue Sources - Revenue from direct sales through distributors was RMB 7.5 million, a 3.1% increase from RMB 7.3 million in the previous year[9]. - Revenue from television platforms dropped significantly by 65.8% to RMB 2.7 million, down from RMB 7.9 million in the previous year[11]. - Online platform sales revenue decreased by 48.5% to RMB 5.5 million from RMB 10.7 million for the six months ended June 30, 2023, due to reduced consumer spending amid poor economic conditions[12]. - Physical sales revenue increased by 61.4% to RMB 40.0 million from RMB 24.8 million for the same period, primarily driven by increased sales of health products[12]. - Kitchenware sales generated RMB 22,555,000, down 30.8% from RMB 32,568,000 in the previous year, while health product sales increased to RMB 33,394,000, up 74.7% from RMB 19,142,000[44]. Economic Environment - The Chinese economy faced challenges, with GDP growth of 4.7% in Q2 2024, below the expected 5.1%[4]. - Retail sales in June 2024 rose only 2%, falling short of the anticipated 3.3% increase[4]. Cost Management - The company plans to continue developing new products that meet consumer demand while implementing strict cost control measures to reduce expenses[4]. - Gross profit margin fell to 11.3% from 32.3%, mainly due to strategic price reductions and a higher proportion of lower-margin health product sales[13]. - Selling and distribution expenses decreased by 35.8% to RMB 10.4 million from RMB 16.2 million, mainly due to reduced agency fees and a lower proportion of sales through television platforms[16]. - Administrative expenses decreased by 16.7% to RMB 9.5 million from RMB 11.4 million, primarily due to reduced employee benefits expenses[17]. - Research and development expenses decreased by 22.2% to RMB 2.8 million from RMB 3.6 million, mainly due to cost control measures implemented by the company[17]. Assets and Liabilities - Trade receivables increased by 38.6% to RMB 41.2 million from RMB 18.4 million, primarily due to health product sales near the reporting period[23]. - Total assets decreased to RMB 153,451,000 as of June 30, 2024, down from RMB 165,740,000 as of December 31, 2023[33]. - Inventory increased significantly to RMB 74,654,000 from RMB 50,180,000, indicating a rise of 48.7%[34]. - Total liabilities increased to RMB 118,638,000 from RMB 107,533,000, reflecting a rise of 10.4%[34]. Shareholder and Corporate Governance - The company has no major acquisitions or investments planned for the mid-term period[28]. - The company did not declare any dividends for the six months ended June 30, 2024[56]. - The company has adopted a set of corporate governance practices in compliance with the corporate governance code, except for the separation of the roles of Chairman and CEO[68]. - The current Chairman and CEO, Ms. Ji, will resign as Chairman effective August 1, 2024, while remaining as Executive Director and CEO[68]. - Mr. Zhao will be appointed as Executive Director, Chairman of the Board, and Chairman of the Nomination Committee effective August 1, 2024[68]. Cash Flow and Financing - Cash used in operating activities was RMB (31,601,000) for the six months ended June 30, 2024, compared to RMB (14,723,000) in the same period of 2023, indicating a significant increase in cash outflow[38]. - The company’s cash and cash equivalents decreased to RMB 2,835,000 as of June 30, 2024, down from RMB 6,983,000 at the end of the previous year[38]. - The company issued shares resulting in net proceeds of RMB 12,263,000 in the previous year, while no such proceeds were recorded in the current period[38]. - The company completed a placement of 42,310,000 new shares at a price of HKD 0.52 per share, raising approximately HKD 21.0 million, with 95.2% of the net proceeds intended for repaying other borrowings[57]. - Approximately 95.2% of the net proceeds, or HKD 20.0 million, will be used to repay other borrowings of the group[69]. - The remaining 4.8%, or HKD 1.0 million, will be allocated for general working capital[69].

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 55,949,000, an increase of 8.6% compared to RMB 51,710,000 for the same period in 2023[1] - Gross profit decreased to RMB 6,298,000, resulting in a gross margin of 11.3%, down from 32.3% in the previous year[1] - Net loss for the period was RMB 23,149,000, compared to a net loss of RMB 20,610,000 in the same period last year[2] - Total revenue for the six months ended June 30, 2024, was RMB 55,949,000, an increase from RMB 51,710,000 for the same period in 2023, representing a growth of 8.6%[9] - The group reported a total loss before tax of RMB 23,122,000 for the six months ended June 30, 2024, compared to a loss of RMB 20,225,000 for the same period in 2023[10] - The group incurred total expenses of RMB 49,651,000 for the six months ended June 30, 2024, compared to RMB 33,316,000 in the previous year, reflecting an increase of 48.9%[13] - The gross profit margin decreased, leading to a net loss increase from RMB 20.6 million to RMB 23.1 million during the same period[22] Revenue Breakdown - Revenue from kitchenware decreased to RMB 22,555,000, down 30.8% from RMB 32,568,000 in the previous year, while health product revenue increased to RMB 33,394,000, up 74.6% from RMB 19,142,000[9] - The revenue from health products accounted for 59.7% of total revenue in the six months ended June 30, 2024, compared to 37.0% in the same period of 2023[24] - Approximately RMB 40,528,000 of revenue for the six months ended June 30, 2024, came from three external customers, each contributing over 10% to total revenue[12] Expenses and Costs - Research and development expenses were RMB 2,798,000, a decrease from RMB 3,568,000 in the previous year[2] - Administrative expenses decreased by 16.7% to RMB 9.5 million, mainly due to reduced employee welfare expenses[35] - Research and development expenses decreased by 22.2% to RMB 2.8 million, primarily due to cost control measures implemented by the company[36] Assets and Liabilities - Total assets as of June 30, 2024, were RMB 153,451,000, down from RMB 165,740,000 as of December 31, 2023[4] - Total liabilities increased to RMB 118,638,000 from RMB 107,533,000 at the end of the previous year[5] - Cash and cash equivalents decreased significantly to RMB 2,835,000 from RMB 33,951,000[4] - Trade receivables net amount as of June 30, 2024, was RMB 41.157 million, compared to RMB 18.406 million as of December 31, 2023, representing a significant increase[17] - The group's current assets net value was approximately RMB 11.6 million, down from RMB 32.9 million as of December 31, 2023[42] - The group's total borrowings amounted to approximately RMB 72.5 million as of June 30, 2024, an increase from RMB 69.5 million as of December 31, 2023[42] - The current ratio as of June 30, 2024, was 1.1 times, down from 1.3 times as of December 31, 2023[43] - The debt-to-equity ratio was 2.1 as of June 30, 2024, compared to 1.2 as of December 31, 2023[43] - The weighted average interest rate on borrowings was approximately 10.32% as of June 30, 2024, up from 9.76% as of December 31, 2023[42] Shareholder Information - The company did not declare any dividends for the six months ended June 30, 2024, and 2023[20] - The company completed a placement of 42,310,000 new shares at a price of HKD 0.52 per share, raising approximately HKD 21.0 million net proceeds[60] - Approximately 95.2% of the net proceeds from the placement will be used to repay other borrowings of the group[60] - As of June 30, 2024, Seashore Global holds 15,000,000 shares, representing approximately 19.84% of the company's equity[52] Corporate Governance - The company has adopted a set of corporate governance practices that comply with the requirements of the corporate governance code[59] - The board believes that having the same person serve as both Chairman and CEO provides strong and consistent leadership for the company[59] - The company has confirmed compliance with the standard code of conduct for securities transactions by directors during the interim period[58] Employment and Management - The group employed 127 employees as of June 30, 2024, a decrease from 205 employees as of December 31, 2023[47] - An independent non-executive director, Mr. Wang Shifang, has signed a service contract with the company for a term of one year starting from June 24, 2023, to June 23, 2024, with a one-month written notice required for termination[61] - Another independent non-executive director, Mr. Li Wei, has a service contract effective from January 25, 2023, to January 24, 2024, also requiring a one-month written notice for termination[61] - An executive director, Ms. Ji Zanyue, has a service contract for three years from June 24, 2021, to June 23, 2024, with a three-month written notice required for termination[61] Market Conditions - The company's sales through online platforms accounted for 9.8% of total revenue for the six months ended June 30, 2024[26] - The company's revenue from direct sales through distributors and physical sales locations was RMB 45.531 million, representing 81.4% of total revenue[26] - Sales revenue from corporate clients decreased by 80.0% to RMB 0.2 million, mainly due to a reduction in sales orders from Chinese property developers[28] - Sales revenue from online platforms decreased by 48.5% to RMB 5.5 million, driven by reduced consumer spending due to economic conditions[29] - Sales revenue from physical retail locations increased by 61.4% to RMB 40.0 million, primarily due to increased sales of health products[30]